ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO775

Myocardiocyte Transcription Factor Cardiac LIM Protein (CSRP3) Mediates Renal Tubular Transcription

Session Information

  • CKD: Mechanisms - III
    November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2103 CKD (Non-Dialysis): Mechanisms

Authors

  • Hutchens, Michael, Portland VA Medical Center, Portland, Oregon, United States
  • Eiwaz, Mahaba B., Oregon Health & Science University, Portland, Oregon, United States
  • Matsushita, Katsuyuki, Kyushu University Hospital, Kyushu, Japan
Background

Cardiac LIM Protein (CSRP3, molecular weight 21 kD), is released from the heart into the systemic circulation after myocardial injury; we recently identified it as an endocrine cardiorenal connector. We hypothesized that modeled release of CSRP3 would alter tubular epithelial cell transcription of renal fibrosis-related genes in vivo and in vitro.

Methods

Cardiac arrest was induced with potassium chloride, and terminated with cardiopulmonary resuscitation (CA/CPR, a model of cardiac injury leading to acute cardiorenal syndrome). CA/CPR or sham procedure was performed in male, 8-12 week old male mice (WT mice). Mice were killed 10h, 24h, 72h, or 7 days later and plasma CSRP3 quantified by ELISA. Recombinant CSRP3 (rCSRP3) was purchased and 1 µg injected intravenously to WT mice. Mice were killed and plasma CSRP3 quantified by ELISA. Curves were fit to model pharmacokinetics. Following injection, mice were perfusion-fixed; the right kidney was snap-frozen and prepared for mRNA measurements and the left paraffin-embedded for immunofluorescence. qPCR for lef1 and tgfb1 mRNA, and CSRP3 immunofluorescence were performed on kidney tissue. Human kidney cells were exposed to 1 µM rCSRP3 or vehicle in translational relevance studies.

Results

CA/CPR resulted greatly increased plasma CSRP3 (max 20.3±3.3 vs. 1.4±0.2 in sham, ng/mL, p=0.04) and remained detectable in plasma at 7 days (5.6±1.6 ng/mL). The 7-day area-under the curve (AUC) was 65 ng/mL*day. The t1/2 for injected rCSRP3, was 86 minutes, and the AUC for a single 1µg dose was 15 ng/mL*days. Immunofluorescence demonstrated CSRP3 within tubular epithelial cell nuclei following injection. Renal tissue mRNA for transforming growth factor beta (tgfb1) was 1.7-(±0.28-fold) increased 6h after rCSRP3 injection, while lef1 mRNA was not regulated. In human tubular epithelial cells, 16h exposure to 1 µM CSRP3 upregulated lef1 mRNA 1.8±0.15-fold compared to vehicle control (p=0.02).

Conclusion

CSRP3, highly specific to cardiomyocytes, is released into the circulation after cardiac injury, and mediates renal transcription of fibrosis-related genes in vivo and in vitro. We postulate this cardiomyocyte transcription factor may play a role in AKI-CKD transition following acute cardiac illness such as cardiac arrest or myocardial infarction.

Funding

  • Veterans Affairs Support